PL448005A1 - Zastosowanie 4-((4-(6-metylobenzotiazoI-2-ylo)fenylo)amino)-sulfol-2-enu do leczenia raka jelita grubego - Google Patents

Zastosowanie 4-((4-(6-metylobenzotiazoI-2-ylo)fenylo)amino)-sulfol-2-enu do leczenia raka jelita grubego

Info

Publication number
PL448005A1
PL448005A1 PL448005A PL44800524A PL448005A1 PL 448005 A1 PL448005 A1 PL 448005A1 PL 448005 A PL448005 A PL 448005A PL 44800524 A PL44800524 A PL 44800524A PL 448005 A1 PL448005 A1 PL 448005A1
Authority
PL
Poland
Prior art keywords
colon cancer
sulfol
methylbenzothiazol
ene
phenyl
Prior art date
Application number
PL448005A
Other languages
English (en)
Other versions
PL248959B1 (pl
Inventor
Magdalena Mizerska-Kowalska
Elżbieta Łastawiecka
Adrianna Sławińska-Brych
Barbara Zdzisińska
Karolina Mrozik
Original Assignee
Uniwersytet Marii Curie-Skłodowskiej
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Marii Curie-Skłodowskiej filed Critical Uniwersytet Marii Curie-Skłodowskiej
Priority to PL448005A priority Critical patent/PL248959B1/pl
Publication of PL448005A1 publication Critical patent/PL448005A1/pl
Publication of PL248959B1 publication Critical patent/PL248959B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Przedmiotem zgłoszenia jest zastosowanie 4-((4-(6-metylobenzotiazol-2-ylo)fenylo)amino)-sulfol-2-enu, o wzorze 1 przedstawionym na rysunku jako fig. 1, do leczenia raka jelita grubego. Związek według wynalazku wykazuje aktywność hamowania proliferacji komórek nowotworowych, zatrzymuje cykl komórkowy i/lub indukuje apoptozę, wykazuje selektywność oddziaływania w stosunku do komórek raka jelita grubego i tożsamych z nimi komórek prawidłowych, to jest ludzkich osteoblastów. Wynalazek rozwiązuje problem techniczny w postaci wskazania zastosowania związku chemicznego jako leku gwarantującego w dużym stopniu skuteczność i bezpieczeństwo stosowania w terapii raka jelita grubego.
PL448005A 2024-03-13 2024-03-13 4-((4-(6-metylobenzotiazoI-2-ylo)fenylo)amino)-sulfol-2-en do zastosowania w leczeniu raka jelita grubego PL248959B1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL448005A PL248959B1 (pl) 2024-03-13 2024-03-13 4-((4-(6-metylobenzotiazoI-2-ylo)fenylo)amino)-sulfol-2-en do zastosowania w leczeniu raka jelita grubego

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL448005A PL248959B1 (pl) 2024-03-13 2024-03-13 4-((4-(6-metylobenzotiazoI-2-ylo)fenylo)amino)-sulfol-2-en do zastosowania w leczeniu raka jelita grubego

Publications (2)

Publication Number Publication Date
PL448005A1 true PL448005A1 (pl) 2025-03-03
PL248959B1 PL248959B1 (pl) 2026-02-16

Family

ID=94771231

Family Applications (1)

Application Number Title Priority Date Filing Date
PL448005A PL248959B1 (pl) 2024-03-13 2024-03-13 4-((4-(6-metylobenzotiazoI-2-ylo)fenylo)amino)-sulfol-2-en do zastosowania w leczeniu raka jelita grubego

Country Status (1)

Country Link
PL (1) PL248959B1 (pl)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012035147A1 (en) * 2010-09-16 2012-03-22 Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Nuclear export inhibitors
WO2014018859A1 (en) * 2012-07-26 2014-01-30 The Scripps Research Institute Klf5 modulators
WO2020144695A1 (en) * 2019-01-09 2020-07-16 Yeda Research And Development Co. Ltd. Modulators of pin1 activity and uses thereof
WO2022197993A1 (en) * 2021-03-19 2022-09-22 Dana-Farber Cancer Institute, Inc. Inhibitors of the peptidyl-prolyl cis/trans isomerase (pin1) and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012035147A1 (en) * 2010-09-16 2012-03-22 Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Nuclear export inhibitors
WO2014018859A1 (en) * 2012-07-26 2014-01-30 The Scripps Research Institute Klf5 modulators
WO2020144695A1 (en) * 2019-01-09 2020-07-16 Yeda Research And Development Co. Ltd. Modulators of pin1 activity and uses thereof
WO2022197993A1 (en) * 2021-03-19 2022-09-22 Dana-Farber Cancer Institute, Inc. Inhibitors of the peptidyl-prolyl cis/trans isomerase (pin1) and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DUBIELLA, C ET AL.: "Nat Chem Biol. 2021, 17, 954-963", SULFOPIN IS A COVALENT INHIBITOR OF PIN1 THAT BLOCKS MYC-DRIVEN TUMORS IN VIVO. *

Also Published As

Publication number Publication date
PL248959B1 (pl) 2026-02-16

Similar Documents

Publication Publication Date Title
ECSP045474A (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6
BRPI0413582B8 (pt) compostos, composições e métodos para inibir a atividade de proteasome
ATE525375T1 (de) Hemmer von janus-kinasen und/oder 3- phosphoinositid-abhängiger protein-kinase 1
ZA202201364B (en) Deuterated compounds for use in the treatment of cancer
EA200870085A1 (ru) Триазолопиридазины в качестве модуляторов тирозинкиназы
GEAP202416530A (en) Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
NZ611654A (en) Treatment of jak2-mediated conditions
MA31336B1 (fr) Inhibiteurs de pi3k alpha a base de pyridopyrimidinone
BR112014000240A2 (pt) derivados de benzilamina como inibidores de calicreína plasmática
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
NO20060091L (no) Anvendelse av kondenserte heterocykliske forbindelser som SCCE-inhibitorer for behandling av hudproblemer eller kreft
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
ATE457312T1 (de) Azaindole als hemmstoffe von c-jun n-terminalen kinasen
MX366498B (es) Inhibidores de calicreina plasmatica.
ECSP088869A (es) Derivados de 2-pirazinona para el tratamiento de enfermedades o condiciones en donde resulta beneficiosa la inhibición de la actividad de la elastasa neutrofílica
CY1117705T1 (el) Νεες ενωσεις διυποκατεστημενης 3,4-διαμινο-3-κυκλοβουτενο-διονης-1,2 για χρηση στην θεραπεια προκαλουμενων απο χημειοκινη ασθενειων
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
AR059710A1 (es) Arilsulfonamidas sustituidas
BR0115936A (pt) 2-anilino-benzimidazóis substituìdos e sua aplicação como inibidores de nhe
MX2022000545A (es) Inhibidores de enzimas.
EA201590066A1 (ru) Дифторгексагидроциклопентаоксазинилы и дифторгексагидробензоксазинилы в качестве ингибиторов бета-секретазы 1
ATE429916T1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
EA201501187A1 (ru) Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
MX2024004899A (es) Compuestos de piperidinilpirazina-carboxamida para tratar y prevenir el cancer y para degradar btk.
PL448005A1 (pl) Zastosowanie 4-((4-(6-metylobenzotiazoI-2-ylo)fenylo)amino)-sulfol-2-enu do leczenia raka jelita grubego